Blow For Pfizer As UK's NICE Rejects Oxbryta For Sickle Cell Disease
Executive Summary
Oxbryta is a highly lauded, first-in-class treatment for sickle cell anemia, a serious and lifelong health condition that can cause pain, infections, organ damage and strokes. But preliminary draft guidance from England’s HTA body says the product is not an acceptable use of National Health Service resources.
You may also be interested in...
Pfizer Ponders Next Move After English HTA Rejects Oxbryta Again Despite Appeal
In spite of successfully appealing against previous negative guidance, Pfizer has again failed to secure a positive recommendation from England’s health technology appraisal institute for Oxbryta for hemolytic anemia caused by sickle cell disease, and has been asked to provide more evidence.
Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.